Prior to rejoining the FDA, Robert Califf was head of medical strategy and Senior Advisor at Alphabet Inc. As a cardiologist, he brings along an extensive clinical research experience. However, a narrow 50 - 46 vote for him shows the controversy about his person, mainly centering around his “close” pharmaceutical industry ties. Janet Woodcock, who served as acting commissioner last year, has agreed to remain at the agency as his principal deputy commissioner. Find more details on Robert Califf here.
Source:
FDA: FDA Organization
Write a comment on this news.